Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C38H51NO4.ClH |
| Molecular Weight | 622.277 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCCCCCCCCCCCC(=O)O[C@H]1C=C[C@H]2[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3C)=C(OCC6=CC=CC=C6)C=C4
InChI
InChIKey=OIJOFEMANOKQAR-VRVMWUCTSA-N
InChI=1S/C38H51NO4.ClH/c1-3-4-5-6-7-8-9-10-11-12-16-19-34(40)42-33-23-21-30-31-26-29-20-22-32(41-27-28-17-14-13-15-18-28)36-35(29)38(30,37(33)43-36)24-25-39(31)2;/h13-15,17-18,20-23,30-31,33,37H,3-12,16,19,24-27H2,1-2H3;1H/t30-,31+,33-,37-,38-;/m0./s1
Myrophine is an opiate analog and long-acting prodrug for morphine with a slow onset of effects. It is weaker than morphine as an analgesic but longer-lasting in effects and was thought to have a more local anesthetic effect than morphine, though with a somewhat greater tendency to cause histamine reactions like itching and rash. In addiction studies conducted in human subjects in the 1950s, myrophine did not substitute for morphine in withdrawal, did not produce notable morphine-like effects, and did not produce addiction or dependence regardless of dose or how it was administered.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8B8YU8Z3NG
Created by
admin on Mon Mar 31 23:08:06 GMT 2025 , Edited by admin on Mon Mar 31 23:08:06 GMT 2025
|
PRIMARY | |||
|
108016-75-7
Created by
admin on Mon Mar 31 23:08:06 GMT 2025 , Edited by admin on Mon Mar 31 23:08:06 GMT 2025
|
PRIMARY | |||
|
46878554
Created by
admin on Mon Mar 31 23:08:06 GMT 2025 , Edited by admin on Mon Mar 31 23:08:06 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
